Equities Analysts Offer Predictions for Monte Rosa Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Research analysts at Wedbush upped their Q2 2024 earnings per share estimates for Monte Rosa Therapeutics in a note issued to investors on Tuesday, May 21st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.37) per share for the quarter, up […]

Related Keywords

,Monte Rosa Therapeutics Inc ,Acadian Asset Management ,Corton Capital Inc ,Vanguard Group Inc ,Nasdaq ,Entrypoint Capital ,Exchange Traded Concepts ,Monte Rosa Therapeutics ,Free Report ,Monte Rosa Therapeutic ,Rosa Therapeutics ,Get Free Report ,Point Capital ,Traded Concepts ,Asset Management ,Vanguard Group ,Monte Rosa Therapeutics Daily ,